Vancouver, British Columbia, Canada, October 31, 2024 – TheNewswire - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) is pleased to announce the results of its annual general meeting of shareholders held on October 30, 2024 (the “Meeting”).

 

All Company matters submitted to the shareholders of the Company for approval as set out in the Company's Notice of Availability of Proxy Materials and Meeting and Management Information Circular (the “Information Circular”), each dated September 18, 2024, were approved by the requisite majority of votes cast at the Meeting. A copy of the Information Circular is available under the Company’s profile at www.sedarplus.ca.  

 

In addition to the presentation of the Company’s audited financial statements of the Company for the financial year ended December 31, 2023 and the Company’s annual benefit report for the financial year ended December 31, 2023, at the Meeting (i) the number of directors of the Company for the following year was set at three (3) directors; (ii) each nominee director set forth in the Information Circular was elected to the Company’s board of directors; (iii) Saturna Group Chartered Professional Accountants LLP were reappointed as the auditors of the Company for the ensuing year; and (iv) the Company’s 20% rolling stock option plan was ratified, confirmed and approved.

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

 

For more information, please contact:

 

Jerry Lai, Investor Relations                                Maryam Marissen, President & CEO

PanGenomic Health Inc.                                PanGenomic Health Inc.

778 743 4642                                                778 743 4642

ir@pangenomic.com                                        info@pangenomic.com

 

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in PanGenomic Health’s disclosure documents which can be found under PanGenomic Health’s profile on www.sedar.com.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.